 Tejas Patil
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 23 | 2023 | 968 | 4.460 |
Why?
| | Lung Neoplasms | 25 | 2023 | 2220 | 3.200 |
Why?
| | Protein-Tyrosine Kinases | 6 | 2023 | 407 | 1.030 |
Why?
| | Proto-Oncogene Proteins | 6 | 2023 | 618 | 1.010 |
Why?
| | Mutation | 11 | 2023 | 3457 | 0.890 |
Why?
| | Brain Neoplasms | 5 | 2023 | 1022 | 0.800 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1390 | 0.770 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 671 | 0.720 |
Why?
| | ErbB Receptors | 9 | 2023 | 569 | 0.660 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 320 | 0.640 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 15 | 0.560 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 18 | 0.560 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 53 | 0.540 |
Why?
| | Adenocarcinoma | 2 | 2018 | 812 | 0.510 |
Why?
| | Protein Kinase Inhibitors | 6 | 2023 | 811 | 0.460 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 237 | 0.350 |
Why?
| | Lung | 2 | 2018 | 3664 | 0.340 |
Why?
| | Gene Rearrangement | 3 | 2018 | 141 | 0.340 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1974 | 0.330 |
Why?
| | Pyrimidines | 2 | 2021 | 382 | 0.320 |
Why?
| | Pyrazoles | 2 | 2021 | 363 | 0.300 |
Why?
| | Neoplasm Staging | 4 | 2019 | 1223 | 0.290 |
Why?
| | Survival Rate | 6 | 2020 | 1720 | 0.290 |
Why?
| | Retrospective Studies | 12 | 2023 | 12978 | 0.270 |
Why?
| | Middle Aged | 15 | 2023 | 27617 | 0.270 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 610 | 0.270 |
Why?
| | Aniline Compounds | 2 | 2023 | 71 | 0.270 |
Why?
| | Central Nervous System | 3 | 2023 | 245 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2023 | 69 | 0.260 |
Why?
| | Humans | 28 | 2023 | 118974 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2021 | 25 | 0.240 |
Why?
| | Oncogenes | 3 | 2022 | 111 | 0.240 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6561 | 0.240 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1059 | 0.230 |
Why?
| | Mesothelioma | 1 | 2023 | 32 | 0.230 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.230 |
Why?
| | Aged | 10 | 2023 | 19657 | 0.220 |
Why?
| | Acrylamides | 1 | 2022 | 42 | 0.210 |
Why?
| | Acetonitriles | 1 | 2021 | 8 | 0.200 |
Why?
| | Pyridines | 2 | 2021 | 440 | 0.190 |
Why?
| | Female | 17 | 2023 | 61565 | 0.190 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 22 | 0.190 |
Why?
| | Gene Amplification | 1 | 2019 | 97 | 0.180 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 47 | 0.170 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.170 |
Why?
| | Lactams | 1 | 2019 | 38 | 0.170 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 18 | 0.170 |
Why?
| | Aminopyridines | 1 | 2019 | 85 | 0.170 |
Why?
| | Piperazines | 1 | 2021 | 316 | 0.170 |
Why?
| | Oncogene Proteins | 1 | 2018 | 52 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 71 | 0.160 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 81 | 0.160 |
Why?
| | Thromboembolism | 1 | 2018 | 99 | 0.160 |
Why?
| | Male | 14 | 2023 | 57801 | 0.160 |
Why?
| | Disease-Free Survival | 2 | 2017 | 649 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 356 | 0.150 |
Why?
| | Prognosis | 3 | 2020 | 3443 | 0.150 |
Why?
| | Biomarkers, Pharmacological | 1 | 2017 | 26 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2017 | 37 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 254 | 0.150 |
Why?
| | Gene Deletion | 1 | 2018 | 361 | 0.150 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 66 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 156 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 900 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4596 | 0.140 |
Why?
| | Adult | 6 | 2023 | 31512 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 628 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2018 | 527 | 0.120 |
Why?
| | Disease Progression | 2 | 2018 | 2490 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2436 | 0.110 |
Why?
| | Incidence | 1 | 2018 | 2424 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2366 | 0.100 |
Why?
| | Smoking | 1 | 2018 | 1487 | 0.100 |
Why?
| | Biomarkers | 1 | 2017 | 3588 | 0.070 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 544 | 0.070 |
Why?
| | Peritoneum | 1 | 2023 | 36 | 0.060 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 8 | 0.060 |
Why?
| | Platinum | 1 | 2023 | 38 | 0.060 |
Why?
| | Sequence Deletion | 1 | 2023 | 171 | 0.060 |
Why?
| | Young Adult | 1 | 2018 | 10793 | 0.060 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 15 | 0.050 |
Why?
| | Taxoids | 1 | 2023 | 98 | 0.050 |
Why?
| | Exons | 1 | 2023 | 307 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2023 | 83 | 0.050 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.050 |
Why?
| | Appendiceal Neoplasms | 1 | 2021 | 14 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 333 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 90 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 229 | 0.040 |
Why?
| | Gene Fusion | 1 | 2018 | 18 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 848 | 0.040 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2017 | 16 | 0.040 |
Why?
| | Etoposide | 1 | 2017 | 149 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 197 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 202 | 0.040 |
Why?
| | Immunotherapy | 1 | 2020 | 493 | 0.040 |
Why?
| | Cranial Irradiation | 1 | 2017 | 70 | 0.040 |
Why?
| | Deoxycytidine | 1 | 2017 | 136 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 842 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 130 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 706 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 198 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1267 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1474 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 462 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 667 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1231 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1166 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 969 | 0.030 |
Why?
| | Mass Screening | 1 | 2020 | 1052 | 0.030 |
Why?
| | Radiosurgery | 1 | 2017 | 318 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1167 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3174 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2874 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 5691 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6412 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 9342 | 0.020 |
Why?
| | Signal Transduction | 1 | 2017 | 4709 | 0.010 |
Why?
| | United States | 1 | 2019 | 12555 | 0.010 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|